Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm
March 28, 2019 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Inogen, Inc., and Spectrum...
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Encourages CRBP Investors to Contact the Firm
March 12, 2019 21:10 ET
|
Bragar Eagel & Squire
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on...
Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
March 12, 2019 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
●Pipeline of rationally-designed synthetic cannabinoids position Corbus to become the leader in treating inflammatory and fibrotic diseases by targeting the endocannabinoid system (ECS)...
Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
March 07, 2019 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Tuesday, March 12 at 8:30 a.m. ET - Norwood, MA, March 07, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
March 04, 2019 09:15 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Advances commercialization strategy for lenabasum ahead of data readouts of key registrational studies in 2020, and potential U.S. Food and Drug Administration (“FDA”) approval and launch in 2021Mr....
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 24, 2019 16:01 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
November 06, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare Conference presentation with...
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
September 20, 2018 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Management to host conference call and webcast this morning at 8:30 a.m. EDTJenrin’s extensive pipeline positions Corbus to be a leader in the treatment of inflammatory and fibrotic diseases with...
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
September 14, 2018 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented Norwood, MA, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings,...
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
August 23, 2018 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the...